The portfolio of A. Menarini GmbH consists of medicinal products for primary patient care, i.e. products that are predominantly prescribed by general practitioners and the appropriate specialists.

Discover more about Menarini Group

All company structures are involved at different levels in the drug manufacturing process...

READ MORE

Efpia Transparency code report STEMLINE

menu

Efpia Transparency code report STEMLINE

Disclosure of data on interactions between the pharmaceutical sector and healthcare professionals as well as healthcare organisations

The data on professional cooperations between Stemline Therapeutics Switzerland GmbH and healthcare professionals (HCPs) as well as healthcare organisations (HCOs) are available on our website since 2016. The data are updated yearly in June and stay published on the website for three years.

Disclosure of these data is a clear commitment to transparency by those pharmaceutical enterprises that have signed the ScienceIndustries Pharma Cooperation Code on the disclosure of benefits with monetary value. They are thus implementing the EFPIA (European Federation of Pharmaceutical Industries and Associations) Disclosure Code.

Professional cooperations between pharmaceutical enterprises and healthcare professionals as well as healthcare organisations has already been well regulated by legal provisions and professional agreements for some time. Areas of application include:

1. Research and development of new medicinal products with the aid of clinical trials conducted at hospitals and universities and by public or private organisations in the health sector;

2. Scientific consultancy;

3. Scientific seminars and conferences held to distribute information and bring those attending up to date;

4. Conferences and further training courses for medical practitioners (Continuing Medical Education – CME) arranged by public sector institutions, universities, specialist organisations and specialized CME providers.

Through the exchange of knowledge between the pharmaceutical sector and healthcare professionals who have sound specialist knowledge and practical experience, valuable information can be imparted that contributes to progress in the health field. This results in more effective therapies and more effective medicines for the health of all patients.

Cooperation is governed by national and international rules and standards. It is based on mutual respect between the partners and recognition of their respective roles. In Switzerland, the Pharma Code and the Pharma Cooperation Code form the basis for the transparent implementation of the ethical and legal provisions and principles. Through the disclosure of pecuniary benefits in the context of cooperations with healthcare professionals and healthcare organisations Stemline Therapeutics Switzerland GmbH and its contracting parties are also publicly declaring their support for those principles.

On the basis of the rules on data protection and privacy, you can access the relevant data for healthcare professionals (HCPs) and healthcare organisations (HCOs) that have consented to disclosure of data. Data for HCPs and HCOs that have not consented to disclosure are available in aggregated form.

Explanatory notes on the disclosure of pecuniary benefits to healthcare professionals and healthcare organizations of Stemline Therapeuticals Switzerland GmbH

The list includes all benefits in kind provided to Healthcare Professionals (HCPs) or Healthcare Organizations (HCOs) with principal address in Switzerland by the Menarini Group in 2023 in connection with events subject to a disclosure requirement. The classification of pecuniary benefits disclosed is based on the rules of the Pharma Cooperation Code and the rules of the EFPIA Code. Stemline Therapeutics Switzerland GmbH’s cooperation with HCPs and HCOs is exclusively project-related and is based on cooperation agreements for a specific performance period. Such agreements normally contain disclosure stipulations in accordance with the Pharma Cooperation Code.

The criterion for disclosure is not the invoice date but the date of the event or undertaking supported. All the expenses of a supported project are shown in total within one disclosure period. Indirect expenses such as issuing invitations for events subject to a disclosure requirement are not disclosed.

The amounts shown are exclusive of VAT. Amounts charged in euros are converted into Swiss francs using the annual average exchange rate.

The HCPs and HCOs named in the list have consented in writing to disclosure of the amounts. Individuals or organizations that did not agree to disclosure of the benefits in kind and amounts for which agreement to disclosure was not obtained are aggregated and reported in anonymized form.

In the case of recurring events involving a working group (e.g. training series) the number of attendees shown in the list corresponds to the rounded average of participants at the individual events.

The contributions of 33% of the total costs which attendees are asked to pay for participation in events of more than half day duration are not included in the support contributions shown in the disclosure template. The amounts shown under the heading Travel and Accommodation comprise the total cost of travel, local transport and hotel expenses including breakfast, reported from a bookkeeping point of view.

In the case of conferences held in the name of several expert associations, the sponsorship contributions are broken down among the individual associations.

With regard to support contributions to hospitals and universities for CME’s and fees for services, the units indicated, are those that have issued the invoice. In the case of sponsorship of universities and comparable organizations, only support contributions for projects with a direct medical connection are reported.

In the case of (scientific) publications used by Stemline Therapeutics Switzerland GmbH as promotional material and not published by an expert association, the fees to the authors are disclosed. Layout and printing expenses are treated as marketing expenses not subject to a disclosure requirement.